Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.
Daclizumab discontinue letter for the US market
Safety Study of Interferon Beta-1a for Acute Stroke
Effects of Gadolinium Contrast Agent Administration on Automatic Brain Tissue Classification of Patients with Multiple Sclerosis.
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses.
FDA approval announcement for ofatumumab
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis.
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.

Pages